DOP2023000155A - Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina - Google Patents
Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabinaInfo
- Publication number
- DOP2023000155A DOP2023000155A DO2023000155A DO2023000155A DOP2023000155A DO P2023000155 A DOP2023000155 A DO P2023000155A DO 2023000155 A DO2023000155 A DO 2023000155A DO 2023000155 A DO2023000155 A DO 2023000155A DO P2023000155 A DOP2023000155 A DO P2023000155A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- gemcitabine
- treatment
- maintenance therapy
- bladder cancer
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583394P | 2017-11-08 | 2017-11-08 | |
| PCT/US2018/059698 WO2019094517A1 (en) | 2017-11-08 | 2018-11-07 | Methods of treatment and maintenance therapy for bladder cancer using gemcitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000155A true DOP2023000155A (es) | 2023-12-29 |
Family
ID=66439297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000155A DOP2023000155A (es) | 2017-11-08 | 2023-08-04 | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10792297B2 (https=) |
| EP (1) | EP3706763A4 (https=) |
| JP (2) | JP2021502347A (https=) |
| KR (3) | KR102892737B1 (https=) |
| CN (1) | CN111787926A (https=) |
| AU (1) | AU2018366106B2 (https=) |
| BR (1) | BR112020008700A2 (https=) |
| CA (1) | CA3081839A1 (https=) |
| DO (1) | DOP2023000155A (https=) |
| EA (1) | EA202091143A1 (https=) |
| IL (2) | IL302714B1 (https=) |
| JO (1) | JOP20200124A1 (https=) |
| MA (1) | MA50581A (https=) |
| MX (2) | MX2020004771A (https=) |
| PE (1) | PE20210041A1 (https=) |
| PH (1) | PH12020550587A1 (https=) |
| SG (1) | SG11202003950WA (https=) |
| WO (1) | WO2019094517A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4124339T (lt) | 2014-03-06 | 2025-11-10 | Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu | |
| BR112020000832A2 (pt) | 2017-07-25 | 2020-07-21 | Taris Biomedical Llc | métodos para tratar metástase tumoral |
| JOP20200124A1 (ar) * | 2017-11-08 | 2020-05-20 | Taris Biomedical Llc | طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك |
| WO2024092159A1 (en) * | 2022-10-28 | 2024-05-02 | Taris Biomedical Llc | Methods of treating bladder cancer with gemcitabine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4111203A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
| AU2003278881A1 (en) | 2002-09-23 | 2004-04-08 | Microchips, Inc. | Micro-reservoir osmotic release systems and microtube array device |
| CA2503193A1 (en) | 2002-10-22 | 2004-05-06 | The Biomerix Corporation | Method and system for intravesicular delivery of therapeutic agents |
| US8361490B2 (en) | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| DK1933810T3 (da) | 2005-08-11 | 2013-01-28 | Childrens Medical Center | Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde |
| WO2007145704A2 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| EP1913962A1 (en) | 2006-10-22 | 2008-04-23 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
| KR101538748B1 (ko) | 2007-12-11 | 2015-07-22 | 메사추세츠 인스티튜트 오브 테크놀로지 | 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법 |
| CA2720523C (en) | 2008-04-04 | 2013-12-17 | Lipella Pharmaceuticals, Inc. | Treatment of bladder dysfunction using liposomal botulinum toxin |
| EP2313122B1 (en) | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Drug delivery medical device |
| EA201170297A1 (ru) | 2008-08-09 | 2011-08-30 | Массачусетс Инститьют Оф Текнолоджи | Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей |
| DK2445570T3 (da) | 2009-06-26 | 2013-02-25 | Taris Biomedical Inc | Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| PL3884988T3 (pl) | 2009-12-17 | 2025-09-08 | Taris Biomedical Llc | Urządzenie implantowalne z tolerancją wewnątrzpęcherzową |
| ES2732150T3 (es) | 2010-01-20 | 2019-11-20 | Urogen Pharma Ltd | Material y método para tratar cavidades internas |
| US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| EP3795121A1 (en) | 2010-08-05 | 2021-03-24 | TARIS Biomedical LLC | Ureteral stent drug delivery device |
| US9457176B2 (en) | 2010-10-06 | 2016-10-04 | Taris Biomedical Llc | Implantable drug delivery device with bladder retention feature |
| WO2012048114A1 (en) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
| MX365807B (es) | 2010-10-27 | 2019-06-14 | Prometic Pharma Smt Ltd | Compuestos y composiciones para el tratamiento del cáncer. |
| WO2012079083A2 (en) | 2010-12-10 | 2012-06-14 | The Board Of Regents Of The University Of Nebraska | Hemodialysis catheter with displaceable tubes to disrupt a fibrous sheath |
| US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| JP2014503554A (ja) | 2011-01-10 | 2014-02-13 | タリス バイオメディカル，インコーポレイテッド | 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン |
| EP2670398B1 (en) | 2011-02-04 | 2017-06-07 | TARIS Biomedical LLC | Implantable device for controlled release of low solubility drug |
| US20150005595A1 (en) | 2011-12-30 | 2015-01-01 | Kibur Medical, Inc. | Implantable devices and methods for evaluation of active agents |
| CN104470535A (zh) | 2012-03-29 | 2015-03-25 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
| WO2013170069A1 (en) | 2012-05-09 | 2013-11-14 | Massachusetts Institute Of Technology | Medicament, method, and drug delivery device for treatment of ovarian cancer |
| MX367070B (es) | 2012-08-31 | 2019-08-05 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. |
| SG11201501424SA (en) | 2012-08-31 | 2015-03-30 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin |
| JP2016508842A (ja) | 2013-03-05 | 2016-03-24 | タリス バイオメディカル エルエルシー | 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法 |
| KR102557326B1 (ko) | 2013-03-15 | 2023-07-19 | 타리스 바이오메디컬 엘엘씨 | 약물-투과성 구성요소를 가지는 약물 전달 장치 |
| EP2968120B1 (en) | 2013-03-15 | 2026-01-14 | TARIS Biomedical LLC | Drug delivery devices and methods for drug delivery |
| CA2944480C (en) | 2013-04-10 | 2021-05-18 | Massachusetts Institute Of Technology | Local drug delivery devices and methods for treating cancer |
| DE102013103986A1 (de) | 2013-04-19 | 2014-10-23 | B. Braun Avitum Ag | Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts |
| KR102385603B1 (ko) | 2013-08-19 | 2022-04-11 | 타리스 바이오메디컬 엘엘씨 | 다중 유닛 약물 전달 장치 및 방법 |
| US9215250B2 (en) | 2013-08-20 | 2015-12-15 | Janus Technologies, Inc. | System and method for remotely managing security and configuration of compute devices |
| EP3065807A1 (en) | 2013-11-05 | 2016-09-14 | TARIS Biomedical LLC | Osmotic drug delivery devices, kits, and methods |
| LT4124339T (lt) * | 2014-03-06 | 2025-11-10 | Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu | |
| RU2591946C2 (ru) | 2014-06-24 | 2016-07-20 | Владимир Эдуардович Анников | Способ изготовления гелеобразного водосодержащего взрывчатого состава |
| KR20220061253A (ko) | 2014-06-26 | 2022-05-12 | 타리스 바이오메디컬 엘엘씨 | 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법 |
| WO2016172704A1 (en) | 2015-04-23 | 2016-10-27 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
| CN118453872A (zh) | 2016-05-06 | 2024-08-09 | 塔里斯生物医药公司 | 治疗下尿路尿道上皮癌的方法 |
| BR112020000832A2 (pt) | 2017-07-25 | 2020-07-21 | Taris Biomedical Llc | métodos para tratar metástase tumoral |
| JOP20200124A1 (ar) | 2017-11-08 | 2020-05-20 | Taris Biomedical Llc | طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك |
| CN112839653A (zh) | 2018-08-01 | 2021-05-25 | 塔里斯生物医药公司 | 使用曲司氯铵治疗膀胱过度活动症的方法 |
-
2018
- 2018-11-07 JO JOP/2020/0124A patent/JOP20200124A1/ar unknown
- 2018-11-07 PE PE2020000538A patent/PE20210041A1/es unknown
- 2018-11-07 KR KR1020247025280A patent/KR102892737B1/ko active Active
- 2018-11-07 EP EP18875446.9A patent/EP3706763A4/en active Pending
- 2018-11-07 CN CN201880084854.9A patent/CN111787926A/zh active Pending
- 2018-11-07 WO PCT/US2018/059698 patent/WO2019094517A1/en not_active Ceased
- 2018-11-07 BR BR112020008700-9A patent/BR112020008700A2/pt unknown
- 2018-11-07 US US16/183,673 patent/US10792297B2/en active Active
- 2018-11-07 SG SG11202003950WA patent/SG11202003950WA/en unknown
- 2018-11-07 JP JP2020524573A patent/JP2021502347A/ja active Pending
- 2018-11-07 MX MX2020004771A patent/MX2020004771A/es unknown
- 2018-11-07 EA EA202091143A patent/EA202091143A1/ru unknown
- 2018-11-07 CA CA3081839A patent/CA3081839A1/en active Pending
- 2018-11-07 MA MA050581A patent/MA50581A/fr unknown
- 2018-11-07 IL IL302714A patent/IL302714B1/en unknown
- 2018-11-07 IL IL274343A patent/IL274343B2/en unknown
- 2018-11-07 KR KR1020207016209A patent/KR20200085822A/ko not_active Ceased
- 2018-11-07 KR KR1020257039507A patent/KR20250174098A/ko active Pending
- 2018-11-07 AU AU2018366106A patent/AU2018366106B2/en active Active
-
2020
- 2020-05-08 PH PH12020550587A patent/PH12020550587A1/en unknown
- 2020-07-13 MX MX2023007680A patent/MX2023007680A/es unknown
- 2020-09-02 US US17/010,648 patent/US12029749B2/en active Active
-
2023
- 2023-03-09 US US18/181,467 patent/US20230321129A1/en active Pending
- 2023-08-04 DO DO2023000155A patent/DOP2023000155A/es unknown
- 2023-10-05 JP JP2023173773A patent/JP2024009888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020004771A (es) | 2020-10-19 |
| IL274343B2 (en) | 2023-10-01 |
| IL302714A (en) | 2023-07-01 |
| EP3706763A1 (en) | 2020-09-16 |
| US20210085705A1 (en) | 2021-03-25 |
| US20190175637A1 (en) | 2019-06-13 |
| JP2021502347A (ja) | 2021-01-28 |
| CN111787926A (zh) | 2020-10-16 |
| MA50581A (fr) | 2020-09-16 |
| PE20210041A1 (es) | 2021-01-08 |
| JP2024009888A (ja) | 2024-01-23 |
| US12029749B2 (en) | 2024-07-09 |
| MX2023007680A (es) | 2023-07-07 |
| WO2019094517A1 (en) | 2019-05-16 |
| BR112020008700A2 (pt) | 2020-10-27 |
| KR102892737B1 (ko) | 2025-11-28 |
| US10792297B2 (en) | 2020-10-06 |
| IL274343B1 (en) | 2023-06-01 |
| PH12020550587A1 (en) | 2021-04-26 |
| CA3081839A1 (en) | 2019-05-16 |
| US20230321129A1 (en) | 2023-10-12 |
| KR20240119176A (ko) | 2024-08-06 |
| KR20250174098A (ko) | 2025-12-11 |
| SG11202003950WA (en) | 2020-05-28 |
| JOP20200124A1 (ar) | 2020-05-20 |
| AU2018366106A1 (en) | 2020-05-14 |
| EP3706763A4 (en) | 2021-08-11 |
| IL302714B1 (en) | 2026-01-01 |
| IL274343A (en) | 2020-06-30 |
| AU2018366106B2 (en) | 2024-11-14 |
| KR20200085822A (ko) | 2020-07-15 |
| EA202091143A1 (ru) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| MX364705B (es) | Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| CO2017007662A2 (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX388914B (es) | Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer. | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
| BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
| MX373231B (es) | Agente anticancerigeno. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX2019001224A (es) | Metodos para tratar el cancer de prostata. | |
| ECSP17014159A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| MX2019015207A (es) | Compuestos para tratar el cancer de ovario. | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| MX2018014938A (es) | Combinaciones farmaceuticas para el tratamiento del cancer. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
| MX386249B (es) | Terapia tusc2 para usarse en el tratamiento de cáncer. |